Business
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the sole placement agent in connection with a $4.0 million private placement for HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics designed to treat diseases driven by chronic inflammation, in
About this update from Hcw Biologics Inc.
[{"type":"image","alt":"E.F. Hutton & Co.","displaySize":"","headline":null,"caption":"E.F. Hutton & Co.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/79443a5b3b67a978aa462ecff663712d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mGrBQbGyYW9D6oYM4uTlWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/79443a5b3b67a978aa462ecff663712d","width":300,"height":169},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/mGrBQbGyYW9D6oYM4uTlWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/79443a5b3b67a978aa462ecff663712d","width":300,"height":169}},"lazy":false},{"type":"text","content":"NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the sole placement agent in connection with a $4.0 million private placement for HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics designed to treat diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated conditions.","length":579,"tagName":"p"},{"type":"text","content":"Joseph T. Rallo, Chief Executive Officer of E.F. Hutton & Co., commented, “We are pleased to have partnered with HCW Biologics on this important financing transaction. HCW Biologics continues to advance a differentiated pipeline of immunotherapeutic candidates targeting significant unmet medical needs. The Company’s proprietary immunotherapeutics represent a novel class of therapeutics that it believes have the potential to fundamentally change the treatment landscape for proinflammatory and senescence-associated diseases, improve patient quality of life, and potentially extend longevity. We look forward to supporting the Company as it progresses its clinical and strategic objectives.”","length":698,"tagName":"p"},{"type":"text","content":"The offering closed on May 21, 2026. HCW Biologics intends to use the net proceeds from the offering to continue clinical trials for HCW9302, advance IND-enabling studies for its T-Cell Engager, HCW11-018b, and its second-generation i...